REGN Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
5.1B
+19.2%
4.3B
+19.0%
3.6B
-7.2%
3.9B
+3.5%
3.8B
Cost of Revenue
573.6M
-0.5%
576.5M
-13.9%
669.4M
+14.5%
584.6M
+12.1%
521.6M
Gross Profit
4.5B
+22.3%
3.7B
+26.5%
2.9B
-11.0%
3.3B
+2.1%
3.2B
Operating Expenses
2.5B
+3.0%
2.4B
+5.6%
2.3B
-5.6%
2.4B
+10.2%
2.2B
R&D
1.8B
+3.3%
1.8B
+6.9%
1.6B
+0.0%
1.6B
+5.6%
1.6B
SG&A
677.8M
+2.4%
662.1M
+2.2%
647.7M
-16.4%
775.0M
+17.8%
657.8M
Operating Income
2.0B
+58.3%
1.3B
+101.2%
642.9M
-26.1%
869.9M
-15.3%
1.0B
EBITDA
2.2B
+53.1%
1.4B
+85.0%
766.1M
-24.5%
1.0B
-12.8%
1.2B
Net Income
1.9B
+50.3%
1.3B
+78.3%
727.2M
-13.9%
844.6M
-42.2%
1.5B
EPS (Basic)
$19.16
+51.8%
$12.62
+80.5%
$6.99
-14.8%
$8.20
-41.8%
$14.09
EPS (Diluted)
$18.45
+50.9%
$12.23
+81.2%
$6.75
-14.1%
$7.86
-42.3%
$13.62
Shares (Diluted)
105.6M
-0.4%
106.0M
-1.6%
107.7M
+0.3%
107.4M
+0.2%
107.2M
Regeneron Pharmaceuticals (REGN) — Financials